Comparison of the efficacy and tolerability of chondroitin plus glucosamine and D-002 (beeswax alcohols) in subjects with osteoarthritis symptoms
DOI:
https://doi.org/10.31053/1853.0605.v74.n2.14479Palabras clave:
D-002, beeswax alcohols, chondroitin sulphate, glucosamine, osteoarthritis, WOMAC score, VAS scoreResumen
Background/AIMS: Osteoarthritis (OA), the commonest joint disorder, is a leading cause of disability. Symptomatic slow-acting drugs for OA (SYSADOA), particularly glucosamine plus chondroitin sulphate (GS/CS), are effective for symptom relief, protect joint cartilage and delay OA progression, with a good safety profile. D-002, a mixture of beeswax alcohols that inhibits both cyclooxygenase and 5-lipoxygenase activities, has been effective in experimental and clinical OA studies, showing also a chondroprotective effect.
OBJECTIVES: To compare the effects of D-002 and GS/SC administered for 12 weeks on OA symptoms.
METHODS: Participants were randomized to GS/CS (375/300 mg) or 50?mg D-002 once daily for 12 weeks. Symptoms were assessed by the Western Ontario and McMaster Individual Osteoarthritis Index (WOMAC) and the visual analogy scale (VAS) scores. The primary outcome was the reduction of the total WOMAC score. Secondary outcomes included WOMAC pain, stiffness and function scores, VAS score and rescue medication consumption.
RESULTS: Of 60 randomized patients, 59 completed the study. D-002 and GS/SC reduced significantly total WOMAC score (72.1% and 78.5%, respectively), and pain, joint stiffness and physical function scores versus baseline. VAS scores decreased significantly with D-002 (76.6%) and GS/SC (76.8%). The reductions, significant from the second week, were enhanced over the trial. Rescue medications were consumed by 3/30 D-002 and 4/30 GS/SC patients. No differences between groups were found. Treatments were well tolerated.
CONCLUSIONS: D-002 (50 mg/day) administered for 12 weeks was safe and comparable to GS/SC for alleviating OA symptoms (pain, stiffness, and functional limitation) (RPCEC00000180).Descargas
Citas
Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197–223.
London: National Institute for Health and Care Excellence; 2014. National Institute for Health and Care Excellence. Osteoarthritis care and management in adults. Clinical Guide 177.
Marshall DA, Vanderby S, Barnabe C, MacDonald KV, Maxwell C, Mosher D, Wasylak T, Lix L, Stat P, Enns E, Frank C, Noseworthy T. Estimating the Burden of Osteoarthritis to Plan for the Future. Arthritis Care Res (Hoboken). 2015, May 4. doi: 10.1002/acr.22612. [Epub ahead of print]
Edwards JJ, Khanna M, Jordan KP, Jordan JL, Bedson J, Dziedzic KS. Quality indicators for the primary care of osteoarthritis: A systematic review. Ann Rheum Dis 2013; 0:1–9.
Allen KD, Bierma-Zeinstra SM, Foster NE, Golightly YM, Hawker G. Osteoarthritis Cartilage 2015; 23(5):826-838.
Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI Recommendations for the management of hip and knee osteoarthritis. Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007; 15 (9): 981-1000.
Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarth Cartilage 2008;16 (2):137–62.
Lee YC, Shmerling RH. The benefit of non-pharmacologic therapy to treat symptomatic osteoarthritis. Curr Rheumatol Rep 2008; 10: 5-10.
Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012; 64 (4):465–74.
McCarberg B, Tenzer P. The complexities in the pharmacologic management of osteoarthritis pain. Curr Med Res Opin 2013; 29: 539-548.
Bruyère O, Cooper C, Pelletier JP, Branco J, Luisa Brandi M, Guillemin F, Hochberg MC, Kanis JA, Kvien TK, Martel-Pelletier J, Rizzoli R, Silverman S, Reginster JY. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014; 44(3):253-63.
Cutolo M, Berenbaum F, Hochberg M, Punzi L, Reginster JY. Commentary on recent therapeutic guidelines for osteoarthritis. Semin Arthritis Rheum 2015 Jun; 44(6):611-7.
Yeomans ND. Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. BMC Med 2015 Mar 19; 13:56.
Bruyere O, Burlet N, Delmas PD, Rizzoli R, Cooper C, Reginster JY. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord. 2008 Dec 16;9:165. doi: 10.1186/1471-2474-9-165.
Hochberg MC, Zhan M, Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin 2008; 24:3029–35.
Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int 2010; 30:357–63.
Henrotin Y, Lambert C. Chondroitin and glucosamine in the management of osteoarthritis: an update. Curr Rheumatol Rep 2013; 15:361.
Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev 2015; 1:CD005614.
Wandel S, Juni P, Tendal B, Nuesch E, Villinger PM, Welton NJ, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010; 341:c4675.
Yang S, Eaton CB, McAlindon TE, Lapane KL. Effects of glucosamine and chondroitin supplementation on knee osteoarthritis: an analysis with marginal structural models. Arthritis Rheumatol. 2015; 67:714-23.
Hochberg MC, Martel-Pelletier J, Monfort J, Möller I, Castillo JR, Arden N, Berenbaum F, Blanco FJ, Conaghan PG, Doménech G, Henrotin Y, Pap T, Richette P, Sawitzke A, du Souich P, Pelletier JP on behalf of the MOVES Investigation Group. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2015 Jan 14. pii: annrheumdis-2014-206792. doi: 10.1136/annrheumdis-2014-206792. [Epub ahead of print]
Mas R. D-002: A product obtained from beeswax. Drugs of the Future. 2001; 26: 731-744.
Pérez Y, Oyarzábal A, Ravelo Y, Mas R, Jiménez S, Molina V. Inhibition of COX and 5-LOX enzymes by D-002 (beeswax alcohols). Curr Top Nutraceutical Res 2014; 12(1/2): 13-18.
Carbajal D, Molina V, Valdés S, Arruzazabala ML, Mas R, Magraner J. Anti-inflammatory activity of D-002: an active product isolated from beeswax. Prostagl. Leukotr. Essent. Fatty Acids 1998; 59: 235-238.
Ravelo Y, Molina V, Carbajal D, Fernández L, Fernández J, Arruzazabala ML, mas R, Hernández C. Evaluation of anti-inflammatory and antinociceptive effects of Abexol (beeswax alcohols). J Nat Med 2010; 65: 330-335.
Mendoza S, Noa M, Valle M, Mendoza N, Mas R. Ameliorating effects of D-002, a mixture of beeswax alcohols, on monosodium iodoacetate-induced osteoarthritis in rats. IJPSRR 2013; 19: 10-15.
Rodríguez I, Mendoza S, Illnait J, Mas R, Fernández JC, Fernández L, Mesa M, Gámez R. Effects of D-002, a mixture of beeswax alcohols, on osteoarthritis symptoms: a randomized placebo-controlled study. IOSRPHR 2012; 2 (6): 1-9.
Puente R, Illnait J, Mas R, Carbajal D, Mendoza S, Fernández JC, Mesa M, Gámez R, Reyes P. Evaluation of the effect of D-002, a mixture of beeswax alcohols, on osteoarthritis symptoms. Korean J Intern Med. 2014;29(2):191-202.
Kim HS. Can natural products serve as potential treatments for osteoarthritis? Korean J Intern Med 2014; 29(2):173-5.
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum 1986; 29 (8): 1039-1049.
Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34 (5): 505-514.
Batlle-Gualda E, Esteve-Vives J, Piera MC, Hargreaves R, Cutis J. Adaptación transcultural al cuestionario WOMAC especifico para artrosis de rodilla y cadera. Rev Esp Reumatol 1999; 26: 38-45.
González V, Marrero D, Sierra R, Velásquez C, Vicente R. Nuevo método por Cromatografía Gaseosa Capilar para el análisis del ingrediente activo D002. Rev CENIC Cien Quim 2008; 39: 123-124.
Angst T, Aeschlimann A, Stuki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implication for required simple sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum 2001; 45: 384-391.
Jinks C, Jordan K, Croft P. Measuring the population impact of knee pain and disability with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Pain 2002; 100: 55-64.
Salaffi F, Leardini G, Canesi B, Mannoni A, Fioravanti A, Caporali R, Lapadula G, Punzi L. Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee. Osteoarthritis Cartilage. 2003;11(8):551-60.
Gruenwald J, Petzold E, Busch R, Petzold HP, Graubaum HJ. Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis. Advances in Therapy 2009; 26: 858-871.
Goregaonkar A, Mathiazhagan KJ, Shah RR, Kapoor PS, Taneja P, Sharma A, Bolmall C, Baliga VP. Comparative assessment of the effectiveness and tolerability of lornoxicam 8 mg BID and diclofenac 50 mg TID in adult Indian patients with osteoarthritis of the hip or knee: A 4-week, double-blind, randomized, comparative, multicenter study. Curr Ther Res 2009; 70 (1): 56-68.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (2): 239-245, 1981.
O’Brien P.C, Shampo M.C. Statistical considerations for performing multiple tests in a single experiment 5. Comparing two therapies with respect to several endpoints. Mayo Clin Proc 1988; 63: 1140-1143.
Srikanth VK, Fryer JL, Zhai G, Winzenberg TM, Hosmer D, Jones G. A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis. Osteoarthritis and Cartilage 2005; 13: 769-781.
Rizzoli R, Boonen S, Brandi ML, Bruyère O, Cooper C, Kanis JA, Kaufman JM, Ringe JD, Weryha G, Reginster JY. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 2013; 29(4): 305-313.
Singh G, Miller D, Lee FH, Pettitt D, Russell MW. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care 2002; 8: S383- S391.
Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martín-Mola E, Paulino J, Marenco JL, Porto A, Laffon A, Araújo D, Figueroa M, Branco J. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007; 56:555–67.
du Souich P. Absorption, distribution and mechanism of action of SYSADOAS. Pharmacol Ther 2014;142:362–74.
Lippiello L, Woodward J, Karpman R, Hammad TA. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res 2000(381):229–40.
Carbajal D, Molina V, Noa M, Valdes S, Arruzazabala ML, Aguiar A, Más R. Effects of D-002 on gastric mucus composition in ethanol-induced ulcer. Pharmacol Res 2000; 42(4): 329-332.
Molina V, Valdés S, Carbajal D, Arruzazabala L, Menéndez R, Mas R. Antioxidant effects of
D-002 on gastric mucosa of rats with experimentally-induced injury. J Med Food 2001; 4: 79-83.
Pérez Y, Oyárzabal A, Mas R, Molina V, Jiménez S. Protective effect of D-002, a mixture of beeswax alcohols, against indomethacin-induced gastric ulcers and mechanism of action. J Nat Medicine 2013; 67: 182-189.
Leffler CT, Philippi AF, Leffler SG, Mosure JC, Kim PD. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med 1999; 164(2):85–91.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
La Revista de la Facultad de Ciencias Médicas de Córdoba (RFCM) adhiere a la política de Acceso Abierto y no cobra cargos a los autores para publicar, ni tampoco a lectores para acceder a los artículos publicados.
